Oral administration with VEN-120 attenuates chronic murine ileitis. A, B] H&E staining demonstrates improved architectural appearance and decreased chronic and acute inflammation following oral administration of VEN-120 or subcutaneous anti-TNF antibody, infliximab [IFX] [*p < 0.05; ***p < 0.0001, Student’s t test]. Flow cytometric analysis demonstrating that VEN-120 administration significantly decreases CD4⁺ burden at C] the LP, and D] at the MLN in TNF^ΔARE/+ mice. Further interrogation of these T cells identified a significant increase in IL-10 at the E] LP but not the F] MLN of TNF^ΔARE/+ mice treated with VEN-120. A significant reduction in IL-17 expressing cells was demonstrated at G] the LP but not H] the MLN of TNF^ΔARE/+ mice treated with VEN-120 [*p < 0.05; **p < 0.01, one-way ANOVA, n = 6]. MLN, mesenteric lymph nodes; LP, lamina propria; ANOVA, analysis of variance; H&E, haematoxylin and eosin; TNF, tumour necrosis factor.